If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for ...

SpringWorks Therapeutics (SWTX) gains EMA panel endorsement for Mirdametinib, a treatment for neurofibromatosis type 1. Read ...

The active substance of Ezmekly, mirdametinib, is a selective, non-competitive mitogen-activated protein kinase 1 and 2 (MEK ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently approved rare ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The ...

SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in Europe. Beyond their initial applications in rare tumors, these small molecules are ...

SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “neutral” rating restated by equities research analysts at Guggenheim in a research note issued to investors on ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) has received a consensus recommendation of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports.

SpringWorks Therapeutics, Inc. announced that it expects the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to issue an opinion on its marketing ...

U.S. stock futures are little changed as investors ready for a busy earrings calendar, including upcoming reports from Apple, ...